12 January 2022 : Clinical Research
Retrospective Study of Surgical Outcomes in 60 Patients with Crohn Disease from a Single Center in Poland
Karolina Majewska1BCDEF*, Cezary Rusinowski1BCD, Beata Jabłońska
2ACDE, Dariusz Gołka3E, Sławomir Mrowiec 2AE
DOI: 10.12659/MSM.934463
Med Sci Monit 2022; 28:e934463
Table 1 The general patient clinical characteristics.
| Mean age | 38 (±10.4) |
| Mean age at diagnosis (years) | 31 (±10) |
| Disease duration (years) | 6.3 (±5.9) |
| Montreal classification: | |
| n=57 | |
| A1 (≤16) | n=1 (1.7%) |
| A2 (17–40) | n=46 (76.7%) |
| A3 (>40) | n=10 (16.7%) |
| n=58 | |
| L1 (ileal) | n=3 (5%) |
| L2 (colonic) | n=9 (15%) |
| L3 (ileocolonic) | n=46 (76.7%) |
| L4 (upper GI – jejunum, duodenum, gaster) | n=4 (7%) |
| L1+L4 (n=1) | |
| L3+L4 (n=3) | |
| n=59 | |
| B16 | n=7 (11.7%) |
| B2 | n=15 (25%) |
| B3 | n=15 (25%) |
| B2+B3 | n=22 (36.7%) |
| Perianal disease (p) | n=11 (18.3%) |
| Presence of fistulae and abscesses* | |
| Fistulae | n=37 (61.7%) |
| Abscesses | n=25 (41.7%) |
| Use of biological therapy n=59 | n=19 (31.7%) |
| Use of glucocorticoids | n=23 (38.3%) |
| Use of azathioprine | n=26 (43.3%) |
| Use of mercaptopurine | n=11 (18.3%) |
| Current smoker n=60 | n=13 (21.7%) |
| BMI n=60 | 20.9 (±3.95) |
| Underweight (<18.5) | n=19 (31.7%) |
| Normal weight (18.5–24.9) | n=32 (53.3%) |
| Overweight (25–29.9) | n=8 (13.3%) |
| Obese (≥30) | n=1 (1.7%) |
| * Current or in medical history. BMI – body mass index. | |